Alnylam Pharmaceuticals (ALNY) Other Working Capital Changes (2009 - 2026)

Alnylam Pharmaceuticals' Other Working Capital Changes history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• Quarterly Other Working Capital Changes rose 110.96% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.3 million (up 91.32% YoY) and the FY2025 annual result came in at -$50.6 million, up 78.49% from the prior year.
• Other Working Capital Changes was $3.0 million for Q1 2026 at Alnylam Pharmaceuticals, up from $2.3 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $75.5 million in Q1 2024 and bottomed at -$61.7 million in Q2 2024.
• A 5-year average of $9.9 million and a median of $6.3 million in 2026 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes surged 225.97% — and 2024, when it sank 548.27%.
• Alnylam Pharmaceuticals' Other Working Capital Changes stood at $24.5 million in 2022, then slipped by 27.67% to $17.7 million in 2023, then plunged by 172.42% to -$12.8 million in 2024, then soared by 117.99% to $2.3 million in 2025, then increased by 29.89% to $3.0 million in 2026.
• Business Quant data shows ALNY's Other Working Capital Changes at $3.0 million in Q1 2026, $2.3 million in Q4 2025, and -$15.1 million in Q3 2025.